BCI Small Molecule Inhibitor for Dusp6 and FGF Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating fibroblast growth factor (FGF) signaling pathways are limited by the lack of specific small molecule inhibitors that can reversibly regulate FGF signaling, making it difficult to dissect the roles of this pathway in development and homeostasis.
Innovation Solution
A small molecule inhibitor, (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI), is identified that blocks the activity of dual specificity phosphatase 6 (Dusp6), a key feedback regulator of FGF signaling, allowing for the modulation of FGF pathway activity in zebrafish embryos and cultured cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional high throughput in vitro screens are used to identify Dusp6 inhibitors, then screening efficiency is improved, but the ability to discover functional inhibitors is worsened because Dusp6 has eluded traditional screens
Solution Approach 1:
The patent uses zebrafish embryos as an intermediary system to bridge the gap between in vitro screening and in vivo function. By treating zebrafish embryos with potential inhibitors and observing phenotypic changes in FGF signaling pathways, the study identifies functional Dusp6 inhibitors that may not be detected by traditional in vitro screens. This intermediary approach allows discovery of inhibitors like BCI that effectively modulate Dusp6 activity in a biologically relevant context.
Solution Approach 2:
The patent replaces traditional mechanical in vitro screening systems with an in vivo zebrafish embryo-based assessment system. This substitution enables the evaluation of compound activity in a living organism where FGF signaling plays critical roles in development, providing more reliable functional inhibition data while maintaining screening throughput through high-content imaging and automated analysis.
2Loss of information
If small molecule inhibitors of Dusp6 are developed to modulate FGF signaling, then the ability to study FGF pathway roles in development is improved, but the complexity of the research system increases
Solution Approach 1:
The patent employs zebrafish embryos as a universal model system that serves multiple functions: it acts as an in vivo screening platform, a developmental biology model, and a tool for studying FGF signaling mechanisms. The same organism enables both high-throughput compound testing and detailed analysis of FGF pathway roles in embryogenesis, thereby reducing the need for multiple separate research systems and minimizing overall complexity.
Solution Approach 2:
The patent utilizes controlled parameter changes in zebrafish development (such as timing of compound administration, concentration gradients, and developmental stage-specific analysis) to dissect FGF signaling functions at different levels. By varying these parameters systematically, the study extracts detailed functional information about FGF pathway roles in development without requiring overly complex experimental designs.
3Quantity of substance
If Dusp6 activity is inhibited to enhance FGF signaling, then FGF target gene expression is improved, but off-target effects and toxicity may worsen
Solution Approach 1:
The patent applies local quality by examining the specificity of BCI's inhibitory effect on Dusp6 versus other phosphatases in the zebrafish system. Through careful analysis of phenotypic outcomes and molecular markers, the study identifies conditions and concentrations where Dusp6 inhibition selectively enhances FGF signaling without causing widespread off-target effects, thereby localizing the beneficial effect to the intended target pathway.
Solution Approach 2:
The patent incorporates feedback mechanisms by monitoring FGF signaling activity and Dusp6 expression levels during BCI treatment in zebrafish embryos. This feedback allows for dynamic adjustment of compound concentration and treatment timing to maximize FGF target gene expression while minimizing toxic effects. The system uses observed phenotypic changes and molecular markers to guide further experimental design and optimize the balance between efficacy and safety.
Data Source
AI summary
Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other uses.